Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline

References

• Global Hepatitis Report 2017. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization.; 2017.
   Google Scholar
• World Health Organization. Combating Hepatitis B and C to reach elimination by 2030. Geneva: WHO; 2016.
   Google Scholar
• World Health Organization. Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Geneva: WHO; 2016.
   Google Scholar
• World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Geneva: WHO; 2016.
   Google Scholar
• Hutin Y, Low-Beer D, Bergeri I, et al. Viral hepatitis strategic information to achieve elimination by 2030: key elements for HIV program managers. JMIR Public Health Surveill. 2017;3(4):e91. doi: 10.2196/publichealth.7370.
   PubMedGoogle Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• World Health Organization – Global Hepatitis Programme. Viral Hepatitis Strategic Information and Modelling Reference Group: meeting report – Appendix 7. Estimating the national attributable mortality from hepatitis B and C virus infection: practical tips for national programme managers. Geneva: World Health Organization; 2016.
   Google Scholar
• Eurostat. Available from: http://ec.europa.eu/eurostat/about/overview.
   Google Scholar
• European Centre for Diseases Prevention and Control. Introduction to the Annual Epidemiological Report - Algorithm for age-standardised rates Stockholm: ECDC; 2017 [cited 2020 Apr 14]. Available from: https://www.ecdc.europa.eu/en/annual-epidemiological-reports/methods.
   Google Scholar
• Cohen J. Statistical power analysis for the behavioural sciences. (2nd ed.). New Jersey, NJ: Lawrence Erlbaum; 1988.
   Google Scholar
• Maucort-Boulch D, de Martel C, Franceschi S, et al. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471–2477.
   PubMed Web of Science ®Google Scholar
• Pimpin L, Cortez-Pinto H, Negro F, et al.; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718–735.
   PubMed Web of Science ®Google Scholar
• European Centre for Diseases Prevention and Control. ECDC Map Maker tool (EMMa). Available from: https://emma.ecdc.europa.eu/Pages/home.aspx.
   Google Scholar
• Akinyemiju T, Abera S, Ahmed M, Alam N, et al. The burden of primary liver cancer and underlying etiologies from 1990 To 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–1691
   PubMed Web of Science ®Google Scholar
• GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1151–1210.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Causes of Death Collaborators. Supplementary appendix 1. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 2017. Available from: https://ars.els-cdn.com/content/image/1-s2.0-S0140673617321529-mmc1.pdf.
   Google Scholar
• Global Burden of Disease Liver Cancer Collaboration. Supplement 1. eAppendix. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015 JAMA oncology. 2017.
   Google Scholar
• EUROSTAT. Causes of death – deaths by country of residence and occurrence. Available from: https://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_cd_aro&lang=en.
   Google Scholar
• Bertuccio P, Bosetti C, Levi F, et al. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24(6):1667–1674.
   PubMed Web of Science ®Google Scholar
• WHO Regional Office for Europe. Alcohol in the European Union - Consumption, harm and policy approaches. Copenhagen: WHO; 2012.
   Google Scholar
• Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42(2):218–224.
   PubMed Web of Science ®Google Scholar
• Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36(5):1206–1213.
   PubMed Web of Science ®Google Scholar
• Oh JK, Shin HR, Lim MK, et al. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer. 2012;12:452.
   PubMed Web of Science ®Google Scholar
• Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23(29):5282–5294.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Cucchetti A, Erroi V, et al. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol. 2013;19(47):8808–8821.
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302–309.
   PubMed Web of Science ®Google Scholar
• Ahlström S, Bloomfield K, Knibbe R. Gender differences in drinking patterns in nine European countries: Descriptive findings. Subst Abus. 2001;22(1):69–85.
   PubMedGoogle Scholar
• Griswold MG, Fullman N, Hawley C, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Supplementary file 2 2018 [updated 2018/09/22/; cited 2020 Apr 20]. Available from: https://www.thelancet.com/cms/10.1016/S0140-6736(18)31310-2/attachment/c502394d-b2cf-4688-a770-e189cb867aba/mmc2.pdf.
   Google Scholar
• Trinchet JC. Hepatocellular carcinoma in 2014: current situation and future prospects. Diagn Interv Imaging. 2014;95(7–8):705–708.
   PubMed Web of Science ®Google Scholar
• Brunot A, Le Sourd S, Pracht M, et al. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016;3:9–18.
   PubMed Web of Science ®Google Scholar
• Borzio M, Dionigi E, Parisi G, et al. Management of hepatocellular carcinoma in the elderly. World J Hepatol. 2015;7(11):1521–1529.
   PubMed Web of Science ®Google Scholar
• Miki D, Aikata H, Uka K, et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2008;43(7):550–557.
   PubMed Web of Science ®Google Scholar
• Feliu A, Filippidis FT, Joossens L, et al. Impact of tobacco control policies on smoking prevalence and quit ratios in 27 European Union countries from 2006 to 2014. Tob Control. 2019;28(1):101–109.
   PubMed Web of Science ®Google Scholar
• World Health Organization – Regional Office for Europe. Status Report on Alcohol and Health in 35 European Countries 2013: WHO; 2013. [cited 2019 Jun 27]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0017/190430/Status-Report-on-Alcohol-and-Health-in-35-European-Countries.pdf.
   Google Scholar
• Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–549.
   PubMed Web of Science ®Google Scholar
• Zatoński WA, Sulkowska U, Mańczuk M, et al. Liver Cirrhosis Mortality in Europe, with Special Attention to Central and Eastern Europe. Eur Addict Res. 2010;16(4):193–201.
   PubMed Web of Science ®Google Scholar
• Guy J, Peters MG. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y). 2013;9(10):633–639.
   PubMedGoogle Scholar
• Chung W, Jo C, Chung WJ, Kim DJ. Liver cirrhosis and cancer: comparison of mortality. Hepatol Int. 2018;12(3):269–276.
   PubMed Web of Science ®Google Scholar
• Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. J Hepatol. 2011;54(5):879–886.
   PubMed Web of Science ®Google Scholar
• Ascione A, Fontanella L, Imparato M, et al. Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years. Liver Int. 2017;37(8):1193–1201.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Pisaturo M, Martini S, et al. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15(10):1337–1349.
   PubMed Web of Science ®Google Scholar
• Hofman R, Nusselder WJ, Veldhuijzen IK, et al. Sterfteaan chronische hepatitis B en C in Nederland 2016. Available from: http://www.liverdoc.nl/wp-content/uploads/1610.Sterfte-aan-chronische-hepatitis-B-en-C-in-NL-Hofman-NTvG-okt-2016.pdf.
   Google Scholar
• Ratib S, West J, Fleming KM. Liver cirrhosis in England—an observational study: are we measuring its burden occurrence correctly?. BMJ Open. 2017;7(7):e013752.
   PubMed Web of Science ®Google Scholar